Jost B.Jonas Mathias Witzens-Harig Lubomir Arseniev Anthony D.Ho

　　Department of Ophthalmology，Medical Faculty Mannheim of the Ruprecht-Karls-University of Heidelberg，Germany Department of Internal Medicine V for Hematology，Oncology and Rheumatology，Ruprecht-Karls-University of Heidelberg，Germany Department of Hematology，Oncology and Hemostaseology，Medical University Hannover，and Cytonet Hannover GmbH，Hannover，Germany. 100005

　　Purpose:To examine feasibility and safety of intravitreal applications of intravitreal autologous bone marrow derived mononuclear cell transplantation.

　　Method:Three patients with end-stage diabetic retinopathy with attached retina，geographic atrophy due to age-related macular degeneration and end-stage glaucomatous optic nerve damage in high myopia with myopic macular degeneration underwent a bone marrow aspiration(100 mL)out of which mononuclear cells were separated.In the first patient，the cell suspension was transsclerally injected into the vitreous cavity.The second and third patient underwent pars plana vitrectomy and fluid-air exchange，and the cell suspensions was dropped onto the macular region.

　　Results:For the first 4 weeks after the procedure，intraocular pressure ranged between 15 and 30 mm Hg.After that period，intraocular pressure normalized without any antiglaucomatous medication taken.At that time，all cell clusters on the retinal surface and in the anterior chamber had disappeared.For all patients，visual acuity was unchanged.

　　Conclusions:Intravitreal autologous bone marrow mononuclear cell transplantation is technically feasible.